Abstract | UNLABELLED: METHODS: 111In-1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid- lanreotide ( DOTA-LAN) scintigraphy (150 MBq; 7 nmol per patient) was performed on 47 patients (28 patients with primary tumors, 19 patients with lung metastases from other tumors) to evaluate the tumor binding in patients with histologically confirmed lung cancer. A group of 27 tumor patients without documented lung lesions served as the control group. Early and delayed planar and SPECT images were acquired. Whole-body scintigraphy was performed at 0.5, 4-6, 24, and 48 h after injection for tumor dose estimation. In addition, hsstr subtype expression and radioligand binding characteristics were studied in vitro using lung tumor samples (n = 15). RESULTS: CONCLUSION: 111In-DOTA-LAN yields high tumor binding for various human lung tumors. Consecutively, radiopeptide therapy may offer a potential new treatment alternative for some lung tumor patients.
|
Authors | T Traub, V Petkov, S Ofluoglu, T Pangerl, M Raderer, B J Fueger, W Schima, A Kurtaran, R Dudczak, I Virgolini |
Journal | Journal of nuclear medicine : official publication, Society of Nuclear Medicine
(J Nucl Med)
Vol. 42
Issue 9
Pg. 1309-15
(Sep 2001)
ISSN: 0161-5505 [Print] United States |
PMID | 11535718
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- DOTALAN
- Heterocyclic Compounds, 1-Ring
- Indium Radioisotopes
- Peptides, Cyclic
- Radiopharmaceuticals
- Somatostatin
|
Topics |
- Case-Control Studies
- Diagnosis, Differential
- Heterocyclic Compounds, 1-Ring
- Indium Radioisotopes
- Lung Neoplasms
(diagnostic imaging, secondary)
- Neoplasm Metastasis
(diagnostic imaging)
- Peptides, Cyclic
- Radiometry
- Radiopharmaceuticals
- Somatostatin
(analogs & derivatives)
- Tomography, Emission-Computed, Single-Photon
|